Table 3

Prevalence of baseline and follow-up serum creatinine monitoring among patients initiating ACE inhibitors or angiotensin receptor blockers according to clinical guideline recommendations

Clinical guidelinesAll initiators
n=223 814 (100%)
NICE heart failureNICE MINICE/UKRA hypertensionNICE CKDGP NotebookWide baseline interval (≤12-months)Ideal baseline interval (≤1 month)
Baseline testingxxxxx169 218 (76%)75 476 (34%)
+Follow-up test ≤2 weeks*xNAxxx46 486 (21%)19 679 (9%)
+Follow-up test ≤3 weeks†70 792 (32%)30 451 (14%)
  • *Follow-up test among those with baseline measurements.

  • †Sensitivity analysis illustrating the importance of 2-week vs 3-week cut-off interval in follow-up test intervals.

  • CKD, chronic kidney disease; GP, general practice; MI, myocardial infarction; NA, not applicable; NICE, National Institute for Health and Care Excellence; UKRA, United Kingdom Renal Association.